mii-exa-mtb-therapieempfehlung-dabrafenib - MII IG Kerndatensatz-Modul Molekulares Tumorboard v2027.0.0-ballot.1

MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Beispiel MedicationRequest: mii-exa-mtb-therapieempfehlung-dabrafenib

German

Profile: MII PR MTB Therapieempfehlung Systemische Therapie version: 2027.0.0-ballot.1

status: Active

intent: Option

medication: Dabrafenib

subject: Maxim Muster (no stated gender), DoB Unknown

authoredOn: 2024-01-01

reasonReference: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

IG © 2024+ Medizininformatik-Initiative. Package de.medizininformatikinitiative.kerndatensatz.mtb#2027.0.0-ballot.1 basiert auf FHIR 4.0.1. Erstellt 2026-09-15
Links: Inhaltsverzeichnis | QA-Bericht | netzwerk-universitaetsmedizin.de | medizininformatik-initiative.de | Impressum
HL7®, FHIR® and the FHIR flame design are registered trademarks of Health Level Seven International. Their use does not constitute endorsement by HL7.